Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515

Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510

RECEIVED SECRETARY OF THE SENATE PUBLIC RECORDS

05 AUG 15 PM 3: 59

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

Pharmaceutical Research	a & Manufacturers of Americ	ea	
Address 1100 15th Street	•	DG 2000E	
	State/Zip (or Country)	DC 20005 USA	
3. Principal Place of Business (if di	ferent from line 2)		
City	State/Zip (or Country)		
4. Contact Name	Telephone E-m	ail (optional)	5. Senate ID#
Marjorie Powell	202-835-3517 mp	owell@phrma.org	31350-12
7. Client Name 🛮 Self			6. House ID #
			30654000
0. Check if this is a Terminat	s a previously filed version of the	on Date	·
O. Check if this filing amends O. Check if this is a Terminat INCOME OR EXP	ion Report Complete Eithe	on Dateer Line 12 OR Line 13	11. No Lobbying
O. Check if this filing amends O. Check if this is a Terminat INCOME OR EXP	ia previously filed version of the ion Report >> Termination >> Termination >> ENSES - Complete Either	on Dateer Line 12 OR Line 13	11. No Lobbying
O. Check if this filing amends INCOME OR EXP 12. Lobb INCOME relating to lobbyin	ia previously filed version of the ion Report >> Termination >> Termination >> ENSES - Complete Either	on Date er Line 12 OR Line 13 13. Orga EXPENSES relating to lobbying	11. No Lobbying
O. Check if this is a Terminat INCOME OR EXPI 12. Lobb INCOME relating to lobbyin period was:	ia previously filed version of the ion Report >> Termination >> Termination >> ENSES - Complete Either	er Line 12 OR Line 13 13. Orga EXPENSES relating to lobbying period were: Less than \$10,000	11. No Lobbying
. Check if this filing amends 0. Check if this is a Terminat INCOME OR EXP 12. Lobb INCOME relating to lobbyin period was: Less than \$10,000	ia previously filed version of the ion Report >> Termination >> Termination >> ENSES - Complete Either	is report on Date on Date The Line 12 OR Line 13 13. Orgate EXPENSES relating to lobbying period were: Less than \$10,000 \$10,000 or more \$\infty\$ >> \$	11. No Lobbying nizations activities for this reporti \$6,260,000.00 Expenses (nearest \$20,000
O. Check if this filing amends O. Check if this is a Terminate INCOME OR EXP 12. Lobb INCOME relating to lobbying period was: Less than \$10,000 \$10,000 or more >>\$ Provide a good faith estimate.	ion Report >> Termination ENSES - Complete Either ying Firms g activities for this reporting Income (nearest \$20,000)	is report on Date The Line 12 OR Line 13 13. Orga EXPENSES relating to lobbying period were: Less than \$10,000 \$10,000 or more \$\times\$ >> \$ 14. REPORTING METHOD. (11. No Lobbying nizations activities for this reporti \$6,260,000.00 Expenses (nearest \$20,000) Check box to indicate ex
O. Check if this is a Terminate INCOME OR EXP 12. Lobb INCOME relating to lobbyin period was: Less than \$10,000 \$10,000 or more >>\$ Provide a good faith estimate \$20,000 of all lobbying relate	ion Report >> Termination ENSES - Complete Either ying Firms g activities for this reporting Income (nearest \$20,000) rounded to the nearest dincome from the client	is report on Date The Line 12 OR Line 13 13. Orga EXPENSES relating to lobbying period were: Less than \$10,000 \$10,000 or more \$\infty\$ >> \$ 14. REPORTING METHOD. (accounting method. See instruction)	11. No Lobbying nizations activities for this reporti \$6,260,000.00 Expenses (nearest \$20,000 Check box to indicate expenses for description of opt
O. Check if this is a Terminate INCOME OR EXP 12. Lobb INCOME relating to lobbyin period was: Less than \$10,000 \$10,000 or more >>\$ Provide a good faith estimate \$20,000 of all lobbying relate	ion Report >> Termination ENSES - Complete Either ying Firms g activities for this reporting Income (nearest \$20,000) rounded to the nearest dincome from the client registrant by any other entity	er Line 12 OR Line 13 13. Orga EXPENSES relating to lobbying period were: Less than \$10,000 \$10,000 or more >> \$ 14. REPORTING METHOD. (accounting method. See instruction)	\$6,260,000.00 Expenses (nearest \$20,000 Check box to indicate expense for description of optots using LDA definitions ts under section 6033(b)

_____ Page 1

OBBYING ACTIVITY. Select as many codes as necessary to rengaged in lobbying on behalf of the client during the reporting penformation as requested. Attach additional page(s) as needed. 5. General issue area code BUD (one per page) 6. Specific Lobbying issues H Rep 109-118, FDA Appropriations, HR 2744-HReport 109-102, FDA Appropriations, Hr 3130 Second Supplemental FY 2005 Approps, FDA Ap S Rep 109-88, FDA Appropriations, S Rept 109-92, FDA Appropriations, The House(s) of Congress and Federal agencies contacted Food & Drug Administration House of Representatives Senate	flect the general issue areas in which the registrant iod. Using a separate page for each code, provide
ngaged in lobbying on behalf of the client during the reporting per aformation as requested. Attach additional page(s) as needed. 5. General issue area code BUD (one per page) 6. Specific Lobbying issues H Rep 109-118, FDA Appropriations, HR 2744-HReport 109-102, FDA Appropriations, Hr 3130 Second Supplemental FY 2005 Approps, FDA Appropriations, S Rep 109-88, FDA Appropriations, S Rept 109-92, FDA Appropriations, 17. House(s) of Congress and Federal agencies contacted Food & Drug Administration House of Representatives	riod. Using a separate page for each code, provide propiations,
 6. Specific Lobbying issues H Rep 109-118, FDA Appropriations, HR 2744-HReport 109-102, FDA Appropriations, Hr 3130 Second Supplemental FY 2005 Approps, FDA Ap S Rep 109-88, FDA Appropriations, S Rept 109-92, FDA Appropriations, 7. House(s) of Congress and Federal agencies contacted Food & Drug Administration House of Representatives 	· · · · · · · · · · · · · · · · · · ·
H Rep 109-118, FDA Appropriations, HR 2744-HReport 109-102, FDA Appropriations, Hr 3130 Second Supplemental FY 2005 Approps, FDA Ap S Rep 109-88, FDA Appropriations, S Rept 109-92, FDA Appropriations, 7. House(s) of Congress and Federal agencies contacted Food & Drug Administration House of Representatives	· · · · · · · · · · · · · · · · · · ·
Food & Drug Administration House of Representatives	☐ Check if None
Senate	
Senate	
8. Name of each individual who acted as a lobbyist in this issue Name	area Covered Official Position (if applicable)
Dodson, Lauryl S	enior Legislative Assistant, Rep. Bobby Rush
Gilbert, Alan	
Grove, Jason	1
Hall, Bryant I	egislative Director, Sen. Bob Graham
Maranchick, Hallie	
Mohler, Dave T.	
Nagle, Brian	
9. Interest of each foreign entity in the specific issues listed on l	ine 16 above 🔀 Check if None
Indicated out I	

Page

Registrant Name:

Pharmaceutical Research & Manufacturers of America

Client Name:

Pharmaceutical Research & Manufacturers of America

Item	Description	Data
18a	Lobbyist Name	Rubin, Peter
18b	Covered Official Position	
18c	New Lobbyist	No
18a	Lobbyist Name	Stein, Peter
18b	Covered Official Position	Sr. Policy Advisor, Sen. Rick Santorum
18c	New Lobbyist	No
18a	Lobbyist Name	Tilton, Steve
18b	Covered Official Position	;
18c	New Lobbyist	No
18a	Lobbyist Name	White, Derrick
18b	Covered Official Position	
18c	New Lobbyist	No

•	Regi	istrant Name:	Pharmaceutical Research & Manufact	turers of America
	Clie	nt Name:	Pharmaceutical Research & Manufact	turers of America
	enga	iged in lobbyin		y to reflect the general issue areas in which the registrant ng period. Using a separate page for each code, provide d.
		General issue Specific Lobb HR 2795, Par	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	
	17.	House of Rep	ongress and Federal agencies contacted resentatives rademark Office	☐ Check if None
	18.	Name of each	individual who acted as a lobbyist in this	Covered Official Position (if applicable)
		Dodson, Lau	ryl	Senior Legislative Assistant, Rep. Bobby Rush
		Fillipone, Ro	bert	Deputy Chief of Staff, Sen. Robert Graham
		Kuhlik, Bruc	e	
		Lietzan, Erik	a King	
		Mohler, Dav	е Т.	·
		Nagle, Brian		
		Patterson, By	ron	
200 To	19.	Interest of eac	h foreign entity in the specific issues liste	d on line 16 above
000	Sign	nature	Filing #26d7a940-67ch-4353-82h	Date _ 8/15/2005

Maniorio Povoll Series Assistant Consul Co	
Printed Name and Title Marjorie Powell - Senior Assistant General Counsel	Page

Client Name: Pharmaceutical Research & Manufacturers of America

Item	Description	Data
18a	Lobbyist Name	Rubin, Peter
18b	Covered Official Position	
18c	New Lobbyist	No
18a	Lobbyist Name	White, Derrick
18b	Covered Official Position	
18c	New Lobbyist	No

C

Re	gistrant Name:	Pharmaceutical Research & Manufact	turers of America
Cli	ent Name:	Pharmaceutical Research & Manufact	turers of America
eng	gaged in lobbyin	TVITY. Select as many codes as necessary on behalf of the client during the reportine acted. Attach additional page(s) as needed	y to reflect the general issue areas in which the registrant ng period. Using a separate page for each code, provide i.
	S 184, Safe I	(I I "8-)	
17.	Department -	Congress and Federal agencies contacted of Health & Human Services Administration	□ Check if None
18.	Name of each	individual who acted as a lobbyist in this	issue area Covered Official Position (if applicable)
	Bermingham	Maya	covered official rosition (if applicable)
	Dodson, Lau	ryl	Senior Legislative Assistant, Rep. Bobby Rush
	Gilbert, Alan Hall, Bryant		Legislative Director, Sen. Bob Graham
	Kuhlik, Bruc	e	
	Lietzan, Erik	a King	·
	Mohler, Dave		
19.	Interest of eac	h foreign entity in the specific issues listed	l on line 16 above 🛛 Check if None
Sim	nature		Date 8/15/2005

_ Page (

Client Name:

Pharmaceutical Research & Manufacturers of America

Item	Description	Data
18a	Lobbyist Name	Nagle, Brian
18b	Covered Official Position	6 -7
18c	New Lobbyist	Yes
18a	Lobbyist Name	Patterson, Byron
18b	Covered Official Position	
18c	New Lobbyist	Yes
18a	Lobbyist Name	Reilly, Lori
18b	Covered Official Position	• '
18c	New Lobbyist	No
18a	Lobbyist Name	Rubin, Peter
18b	Covered Official Position	· · · · · · · · · · · · · · · · · · ·
18c	New Lobbyist	No
18a	Lobbyist Name	Stein, Peter
18b	Covered Official Position	Sr. Policy Advisor, Sen. Rick Santorum
18c	New Lobbyist	No
18a	Lobbyist Name	Tilton, Steve
18b	Covered Official Position	,
18c	New Lobbyist	No
18a	Lobbyist Name	White, Derrick
18b	Covered Official Position	··· , — ·······
18c	New Lobbyist	No
	1	

Registrant Name: Pharmaceutical Research	& Manufacturers of America
Client Name: Pharmaceutical Research &	& Manufacturers of America
LOBBYING ACTIVITY. Select as many codes engaged in lobbying on behalf of the client during information as requested. Attach additional page(s as necessary to reflect the general issue areas in which the registrant g the reporting period. Using a separate page for each code, provide (s) as needed.
 15. General issue area code MMM (or 16. Specific Lobbying issues Executive Branch Medicare reimbursement 	ne per page) ent issues
7. House(s) of Congress and Federal agencies of Agency for Health Care Research and Queenters for Medicare and Medicaid Services.	ıality
8. Name of each individual who acted as a lobb	Oyist in this issue area Covered Official Position (if applicable)
	1
Name	1
Name Bermingham, Maya	1
Name Bermingham, Maya Brigner, Sharon	Covered Official Position (if applicable)
Name Bermingham, Maya Brigner, Sharon Burkholder, Randy	Covered Official Position (if applicable) Senior Legislative Assistant, Rep. Bobby Rush
Name Bermingham, Maya Brigner, Sharon Burkholder, Randy Dodson, Lauryl	Covered Official Position (if applicable)
Bermingham, Maya Brigner, Sharon Burkholder, Randy Dodson, Lauryl Fillipone, Robert	Covered Official Position (if applicable) Senior Legislative Assistant, Rep. Bobby Rush
Name Bermingham, Maya Brigner, Sharon Burkholder, Randy Dodson, Lauryl Fillipone, Robert Gilbert, Alan	Covered Official Position (if applicable) Senior Legislative Assistant, Rep. Bobby Rush Deputy Chief of Staff, Sen. Robert Graham Legislative Assistant, Reb. Ralph Regula

 \Box

Client Name: Pharmaceutical Research & Manufacturers of America

Item	Description	Data
18a	Lobbyist Name	Hall, Bryant
18b	Covered Official Position	Legislative Director, Sen. Bob Graham
18c	New Lobbyist	No
18a	Lobbyist Name	Kaplan, Ann
18b	Covered Official Position	• ,
18c	New Lobbyist	No
18a	Lobbyist Name	Krasner, Wendy
18b	Covered Official Position	, ,
18c	New Lobbyist	No
18a	Lobbyist Name	Maranchick, Hallie
18b	Covered Official Position	, -
18c	New Lobbyist	Yes
18a	Lobbyist Name	Mohler, Dave T.
l8b	Covered Official Position	·,
18c	New Lobbyist	No
18a	Lobbyist Name	Nagle, Brian
l8b	Covered Official Position	•
18c	New Lobbyist	Yes
8a	Lobbyist Name	Patterson, Byron
8b	Covered Official Position	• •
.8c	New Lobbyist	Yes
8a	Lobbyist Name	Rubin, Peter
8b	Covered Official Position	
8c	New Lobbyist	No
8a	Lobbyist Name	Smith, Richard
8b	Covered Official Position	
8c	New Lobbyist	No
8a	Lobbyist Name	Stein, Peter
8b	Covered Official Position	Sr. Policy Advisor, Sen. Rick Santorum
8c	New Lobbyist	No
8a	Lobbyist Name	Stemple, Niko
8b	Covered Official Position	
8c	New Lobbyist	No
8a	Lobbyist Name	Strawn, Heather
8b 8c	Covered Official Position New Lobbyist	Vac
		Yes
8a	Lobbyist Name	Tilton, Steve
8b	Covered Official Position	
8c	New Lobbyist	No
Ba	Lobbyist Name	Van Meter, Jennifer
8b	Covered Official Position	· was statuted a generaliza
8a 8b 8c 3a	New Lobbyist	No
3a	Lobbyist Name	White, Derrick
	•	vidice, Dellier
	İ	·

Registrant Name:	Pharmaceutical Research & Manufacturers of America
	· · · · · · · · · · · · · · · · · · ·

Client Name: Pharmaceutical Research & Manufacturers of America

Item	Description	Data	
18b 18c	Covered Official Position New Lobbyist	No	

urers of America
urers of America
y to reflect the general issue areas in which the registrant ng period. Using a separate page for each code, provide l.
tax credit, x credit,
,
☐ Check if None
issue area
Covered Official Position (if applicable)
Legislative Director, Sen. Bob Graham
Sr. Policy Advisor, Sen. Rick Santorum
I
d on line 16 above Check if None
Date 8/15/2005

ient Name:	<u>Pharmaceut</u>	ical Research & Manufact	urers of America
ngaged in lobby	ing on behalf of	t as many codes as necessary the client during the reporting additional page(s) as needed	y to reflect the general issue areas in which the registrant ng period. Using a separate page for each code, provide l.
5. General issu	e area code 🛭	OR (one per page)	
	obying issues et BioShield Ac	t of 2004, Liability provision	ons
17. House(s) of Senate	Congress and F	ederal agencies contacted	☐ Check if None
18. Name of eac	h individual wh	o acted as a lobbyist in this i	issue area
8. Name of eac	h individual wh	o acted as a lobbyist in this i	issue area Covered Official Position (if applicable)
		o acted as a lobbyist in this i	
Name	m, Maya	o acted as a lobbyist in this	
Name Berminghan Kuhlik, Bru	m, Maya ace		
Name Bermingha Kuhlik, Bru Lietzan, Er	m, Maya nce ika King		Covered Official Position (if applicable)
Name Berminghan Kuhlik, Bru Lietzan, Er Stein, Peter	m, Maya ace ika King		
Name Bermingha Kuhlik, Bru Lietzan, Er	m, Maya ace ika King		Covered Official Position (if applicable)
Name Berminghan Kuhlik, Bru Lietzan, Er Stein, Peter	m, Maya ace ika King		Covered Official Position (if applicable)
Name Berminghan Kuhlik, Bru Lietzan, Er Stein, Peter	m, Maya ace ika King		Covered Official Position (if applicable)
Name Berminghan Kuhlik, Bru Lietzan, Er Stein, Peter Strawn, He	m, Maya nce ika King ather		Covered Official Position (if applicable) Sr. Policy Advisor, Sen. Rick Santorum

Registrant Name: Pharmaceutical Rese	earch & Manufacturers of America
Client Name: Pharmaceutical Rese	earch & Manufacturers of America
engaged in lobbying on behalf of the clien information as requested. Attach additional	
16. Specific Lobbying issues	(one per page) ral American Free Trade Agreement Implementation Act, CAFTA ctual property abroad
17. House(s) of Congress and Federal ag House of Representatives Senate of U.S. Trade Representati	
Schate of O.S. Trade Representati	•
18. Name of each individual who acted a	as a lobbyist in this issue area Covered Official Position (if applicable)
18. Name of each individual who acted a	1
18. Name of each individual who acted a	Covered Official Position (if applicable)
18. Name of each individual who acted a Name Fillipone, Robert Finston, Susan	Covered Official Position (if applicable)
18. Name of each individual who acted a Name Fillipone, Robert Finston, Susan Gilbert, Alan	Covered Official Position (if applicable)
18. Name of each individual who acted a Name Fillipone, Robert Finston, Susan Gilbert, Alan Maranchick, Hallie	Covered Official Position (if applicable)
18. Name of each individual who acted a Name Fillipone, Robert Finston, Susan Gilbert, Alan Maranchick, Hallie Mohler, Dave T.	Covered Official Position (if applicable)
18. Name of each individual who acted a Name Fillipone, Robert Finston, Susan Gilbert, Alan Maranchick, Hallie Mohler, Dave T. Ritter, Geralyn	Covered Official Position (if applicable)
18. Name of each individual who acted a Name Fillipone, Robert Finston, Susan Gilbert, Alan Maranchick, Hallie Mohler, Dave T. Ritter, Geralyn Rubin, Peter 19. Interest of each foreign entity in the	Covered Official Position (if applicable)
18. Name of each individual who acted a Name Fillipone, Robert Finston, Susan Gilbert, Alan Maranchick, Hallie Mohler, Dave T. Ritter, Geralyn Rubin, Peter	Covered Official Position (if applicable) Deputy, Chief of Staff, Sen. Robert Graham

Client Name:

Pharmaceutical Research & Manufacturers of America

Item	Description	Data
18a	Lobbyist Name	Toohey, Brian
18b	Covered Official Position	·
18c	New Lobbyist	No
18a	Lobbyist Name	White, Derrick
18b	Covered Official Position	
18c	New Lobbyist	No

/IICIIl	Name:	a marridacisci i				
C			l Research & Manufac			<u></u>
	Client new add		- Complete ONLY whe	re registration informatio	n has changed.	
		- 				
21.	Client new prin	cipal place of business	(if different from line 20)			
City			State/Zip (or Country)			
22.	New general de	escription of client's bu	siness or activities			
LOI	BBYIST U	PDATE			·	
	Name of eac Bantham, I Bello, Judit Finston, Su Lietzan, Er	Russel th san	rted individual who is ne	o longer expected to act as a	a lobbyist for the client	
ISSI	UE UPDAT	rr				
			ously reported that no lo	nger pertain		
			·			
		ORGANIZAT				
Z3.	Add the foll	owing affiliated o	rganization(s)			
		Name		Address	Principal Place of (city and state or	
26.	Name of eac	ch previously repo	rted organization that is	no longer affiliated with the	e registrant or client	
				·		
	REIGN EN	TITIES owing foreign ent	itiaa		100	
	7 tad the 1011	owing foreign cit.	nies	Principal Place of Busi	ness Amount of contribution	ı Ov
	Name		Address	(city and state or count		1
		ch previously repo organization	rted foreign entity that n	o longer owns, or controls,	or is affiliated with the regi	strant,
		1/10	· · //			

tem Description Data Lobbylst Update Kuhlik, Bruce Krasner, Wendy Krasner, Wendy	
3 Lobbyist Update Krasner, Wendy	

•